Investors

Press Releases

Date Title View
Toggle Summary Momenta Pharmaceuticals Announces Presentation on M281, an Anti-FcRn Monoclonal Antibody, at 11th International Congress on Autoimmunity
CAMBRIDGE, Mass. , May 17, 2018 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) today announced the upcoming presentation describing the broad potential for anti-FcRn therapeutics and the discovery of M281. The presentation will be part of the 11 th International Congress on
View HTML
Toggle Summary Momenta Pharmaceuticals to Webcast Presentation at the Bank of America Merrill Lynch Health Care Conference 2018
CAMBRIDGE, Mass. , May 10, 2018 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that it will present at the Bank of America Merrill Lynch Health Care Conference 2018.  The
View HTML
Toggle Summary Momenta Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Corporate Update
CAMBRIDGE, Mass. , May 08, 2018 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA) today reported its financial results for the first quarter ended March 31, 2018 and provided a corporate update. “We made important progress in the first quarter of 2018 across our complex generic,
View HTML
Toggle Summary Momenta Pharmaceuticals Announces Date of First Quarter 2018 Financial Results Conference Call and Webcast
CAMBRIDGE, Mass. , May 01, 2018 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), today announced that it will release its financial results for the first quarter ended March 31, 2018 and provide a corporate update before the U.S. financial markets open on Tuesday, May 8 , 2018.   
View HTML
Toggle Summary Momenta Pharmaceuticals to Webcast Presentation at Two Upcoming Investor Conferences
CAMBRIDGE, Mass. , March 05, 2018 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that it will webcast its presentation at two upcoming investor conferences.
View HTML
Toggle Summary Momenta Pharmaceuticals Reports Fourth Quarter and Year End 2017 Financial Results and Provides Corporate Update
--Ended 2017 with a healthy cash position of $380M -- --Recently announced FDA approval and launch of Glatopa ® 40 mg-- CAMBRIDGE, Mass. , Feb. 21, 2018 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA) today reported its financial results for the fourth quarter and year ended
View HTML
Toggle Summary Momenta Pharmaceuticals Announces FDA Approval and Launch of Glatopa® (glatiramer acetate injection) 40 mg/mL
--Glatopa 40 mg/mL is a fully substitutable, AP-rated generic version of three times-a-week COPAXONE ® (glatiramer acetate injection) 40 mg/mL for the treatment of patients with relapsing forms of multiple sclerosis (MS)-- --Glatopa 40 mg/mL joins the Sandoz glatiramer acetate injection portfolio
View HTML
Toggle Summary Momenta Pharmaceuticals to Webcast Presentation at the LEERINK Partners 7th Annual Global Healthcare Conference
CAMBRIDGE, Mass. , Feb. 08, 2018 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that it will webcast its presentation at the LEERINK Partners 7th Annual Global Healthcare
View HTML
Toggle Summary Momenta Pharmaceuticals Announces Date of Fourth Quarter and Year End 2017 Financial Results Conference Call and Webcast
CAMBRIDGE, Mass. , Feb. 07, 2018 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, will release its financial results for the fourth quarter and year ended December 31, 2017 before the U.S.
View HTML
Toggle Summary Momenta Pharmaceuticals Announces Positive Outcome for Contracted Glatopa® (glatiramer acetate injection) Fill/Finish Manufacturer
-- McPherson, Kansas facility compliance status amended to Voluntary Action Indicated (VAI)--  -- VAI status provides the potential for the near-term FDA approval of Sandoz’s Glatopa 40 mg ANDA-- CAMBRIDGE, Mass. , Jan. 30, 2018 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc.
View HTML